𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model

✍ Scribed by Bozec, A; Sudaka, A; Fischel, J-L; Brunstein, M-C; Etienne-Grimaldi, M-C; Milano, G

Book ID
109999524
Publisher
Nature Publishing Group
Year
2008
Tongue
English
Weight
236 KB
Volume
99
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A novel orthotopic mouse model of head a
A novel orthotopic mouse model of head and neck cancer with molecular imaging
✍ Nishant P. Reddy; Shunsuke Miyamoto; Koji Araki; Tingyan Liu; Michael Feldman; B πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 509 KB

## Abstract ## Objectives/Hypothesis: Our goal was to develop a noninvasive, dynamic imaging method that would further the understanding of head and neck cancer (HNC) tumor growth and local spreading. We developed a novel orthotopic mouse model of HNC with a stable cell line expressing a red fluor

Morbidity of supraomohyoidal and modifie
Morbidity of supraomohyoidal and modified radical neck dissection combined with radiotherapy for head and neck cancer. A prospective longitudinal study
✍ Alexander Ahlberg; Polymnia Nikolaidis; Therese EngstrΓΆm; Karin Gunnarsson; Hemm πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 212 KB

## Abstract ## Background The purpose of this study was to show the investigated impact of supraomohyoidal neck dissection and modified radical neck dissection, both combined with radiotherapy, on cervical range of motion (CROM), mouth opening, swallowing, lymphedema, and shoulder function. ## Me

A phase II study of piritrexim in combin
A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer
✍ Everett E. Vokes; Isaiah W. Dimery; Charlotte D. Jacobs; Daniel Karp; Arturo Mol πŸ“‚ Article πŸ“… 1991 πŸ› John Wiley and Sons 🌐 English βš– 468 KB πŸ‘ 2 views

Thirty patients with recurrent and/or metastatic head and neck cancer were treated with sequentially administered methotrexate (MTX) and piritrexim (PTX). The treatment schedule consisted of intravenous (IV) MTX (50 mg/m') administered on day 1 and oral PTX (75 mg/mz) administered twice daily on day